Curated News
By: NewsRamp Editorial Staff
October 16, 2026
Redwood AI Joins Terry Fox Grant for AI Drug Development
TLDR
- Redwood AI joins a competitive Terry Fox grant, positioning its AI to speed drug development and gain an edge in life sciences.
- Redwood AI contributes data integration and modelling to test if causal AI with clinical and genomic data improves therapy predictions.
- Redwood AI's collaboration aims to accelerate therapy development, potentially bringing better treatments to patients sooner and improving lives.
- Redwood AI explores causal AI with chemical modelling to predict drug trial outcomes, blending AI and chemistry for medical breakthroughs.
Impact - Why it Matters
This collaboration underscores the growing role of artificial intelligence in accelerating drug discovery and development. By combining causal AI with preclinical and real-world data, the project could lead to more accurate predictions of therapy performance in human trials, potentially reducing the time and cost of bringing new treatments to patients. For Redwood AI, this expands its life sciences applications and demonstrates the versatility of its technology beyond cybersecurity. For the broader industry, it highlights how AI and chemical modelling can work together to streamline research and improve success rates in oncology, ultimately benefiting patients and investors alike.
Summary
Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) has joined a Canadian oncology research consortium as a co-applicant in a competitive Terry Fox Research Institute grant. The project will support the development of Onco-Innovations’ SynoGraph™ artificial intelligence platform, which aims to use causal AI to improve predictions of how investigational therapies may perform in human trials. Redwood AI will contribute proprietary data integration, feature engineering, and physicochemical modelling methods, working alongside Onco-Innovations and academic research partners who will supply clinical and genomic datasets. The collaboration expands Redwood AI’s applications in life sciences and highlights the potential of combining AI with chemical modelling to support drug development.
Redwood AI is a technology company developing advanced artificial intelligence and cybersecurity solutions for defense, public safety, and life sciences. The company applies artificial intelligence across quantum cybersecurity, scientific research, and advanced chemistry applications. Its technology is designed to help organizations prepare for quantum-enabled cybersecurity threats while enabling faster, more efficient development of new therapies and chemistry-driven applications. The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF.
The announcement was disseminated through AINewsWire, a specialized communications platform focused on the latest advancements in artificial intelligence, including the technologies, trends, and trailblazers driving innovation forward. AINewsWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Redwood AI Joins Terry Fox Grant for AI Drug Development
